Please login to the form below
HTA guidance from NICE, the SMC and the AWMSG
Here we present a feed of upcoming health technology assessment (HTA) decisions, covering appraisals by the National Institute of Health and Care Excellence (NICE), the Scottish Medicines Consortium (SMC) and the All Wales Medicines Strategy Group (AWMSG).
Provided by Guidelines, it also features: NICE clinical guidelines, NICE quality standards, NICE evidence updates, NICE evidence summaries, independent professional body guidelines and (Scottish Intercollegiate Guidelines Network (SIGN) guidance.
Combined hormonal contraception—update (Faculty of Sexual & Reproductive Healthcare)
September 2018: Independent professional body guideline
Asthma (update)
September 2018: NICE Quality Standard
Depression in adults (update)
September 2018: NICE Quality Standard
Eating disorders
September 2018: NICE Quality Standard
Ovarian cancer (refresh)
September 2018: SIGN guidance
Renal replacement therapy
October 2018: NICE Clinical Guideline
Decision making and mental capacity
October 2018: NICE Social Care Guidance
Foetal alcohol spectrum disorder (update)
October 2018: SIGN guidance
Abdominal aortic aneurysm: diagnosis and management
November 2018: NICE Clinical Guideline
Contraceptive choices for women who are obese/overweight
November 2018: Independent professional body guideline
NICE approves BioMarin’s Brineura after initial setback
12 Sep 2019
The positive recommendation of Brineura was agreed by NICE’s Highly Specialised Technology committee. ... NICE seems to have jumped the gun, approving the therapy before the review of the new data.
Novartis’ CAR-T Kymriah scores SMC approval
10 Sep 2019
treatments. The medicine went through the SMC’s Patient and Clinician Engagement (PACE) process, which considers medicines that treat end of life and rare conditions. ... Following this recommendation, the cost-effectiveness watchdog then recommended
NICE backs NHS use of Novartis’ gene therapy Luxturna
4 Sep 2019
The Scottish Medicines Consortium (SMC) is due to deliver its verdict on the gene therapy in December. ... We are delighted with today’s decision by NICE to recommend voretigene neparvovec for use in patients with vision loss due to a genetic mutation
Early ‘no’ for GW Pharma’s epilepsy drug, but NICE vows to collaborate
23 Aug 2019
Judgement arrives ahead of European approval. GW Pharma’s Epidyolex for two types of severe treatment-resistant epilepsy has been given a preliminary rejection by England’s NICE – but the cost ... We remain hopeful that NICE will recommend
NICE’s long-serving chief exec Sir Andrew Dillon to step down
22 Aug 2019
Sir Andrew has led NICE with a laser focus on establishing how the latest medicines can benefit patients and the NHS.". ... The board of NICE says it will make arrangements to advertise the chief executive’s post during the autumn.
MGP’s Guidelines brand is trusted by over 58,000 healthcare professionals for concise clinical summaries of major primary and shared care guidelines in the UK. Through Guidelines, Guidelines for Nurses and Guidelines in Practice, MGP connect pharmaceutical and medical device companies to an engaged audience of GPs, GP commissioners and payers, nurses and allied healthcare professionals.
To discuss how we can support your guidance or implementation needs please contact marketing@mgp.co.uk
Featured jobs
-
Account Director – UK Office
-
Excellent salary and benefits
- Account Manager – Healthcare advertising
-
Salary TBC
Subscribe to our email news alerts
PMHub
Cello Health
Cello Health are expert navigators, helping healthcare clients uncover hidden insights, explore scientific options and make difficult strategic choices...
Quick links
Infographics
